AcroCyte Therapeutics Inc.

AcroCyte Therapeutics Inc. develops the R³CE® (Rapid, Reproducible, Rare Cell 3D Expansion) platform—an FDA-designated Class I, scaffold-free system that rapidly expands minimal patient specimens including circulating tumor cells, needle biopsies, and frozen tissues into functional 3D organoids within days. The company offers R³CE® culture plates and specialized media for research and clinical applications, alongside the Onco-REAL™ clinical diagnostic service providing comprehensive functional analysis from liquid biopsies to support oncology treatment decisions. AcroCyte's technology platform enables drug developers to accelerate preclinical screening, clinicians to deliver personalized ex vivo drug sensitivity testing, and researchers to create customized 3D models that replicate physiological conditions. The platform eliminates reliance on traditional cell lines and animal models, addressing key limitations in reproducibility, speed, and sample efficiency for precision medicine applications across oncology, regenerative medicine, and drug discovery.